Leukemia, Biphenotypic, Acute: all 117 studies
Page 1 of 2. Open to participants first (51), then studies with results posted, then the rest; newest registration first within each.
- Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic SyndromeNot yet recruitingNCT07819396Phase 2
- Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic MalignanciesNot yet recruitingNCT07710781Not applicable
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingNCT07636564Phase 2
- Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid LeukemiaRecruitingNCT07537738
- HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).Enrolling by invitationNCT07517510Phase 2
- A Study of Revumenib and Mezigdomide in People With LeukemiaRecruitingNCT07356154Phase 1/2
- Orca-T Expanded Access Program Study for Patients With Advanced Hematologic MalignanciesAvailableNCT07346105
- Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell TransplantationRecruitingNCT07256210Phase 2
- Prophylactic DLI-X for Leukemia Relapse After HCTNot yet recruitingNCT07254793Phase 1
- Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT07222579Phase 2
- Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeRecruitingNCT07216443Phase 2
- Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid NeoplasmsRecruitingNCT07094750Not applicable
- Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid CancerRecruitingNCT07046078Phase 2
- Real World Asparaginase Therapy ToxicityNot yet recruitingNCT07008027
- Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of RelapseRecruitingNCT06928662Phase 1/2
- Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with HemoblastosisRecruitingNCT06756152Phase 2/3
- Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell TransplantRecruitingNCT06575296Phase 1
- Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCTRecruitingNCT06551584Phase 1
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)RecruitingNCT06533579Phase 1/2
- Vitamin A and D Supplementation in Allogeneic HCTRecruitingNCT06508099Phase 2
- BeFluBu vs FluBuRux Conditioning in Haploidentical HCTRecruitingNCT06477549Phase 2
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT06390319Phase 2
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingNCT06317662Phase 2
- Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/LymphomaRecruitingNCT06289673Phase 4
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingNCT06177067Phase 1
- Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic DiseasesRecruitingNCT06013423Phase 2
- Venetoclax Combined With Azactidine in the Treatment of ALALRecruitingNCT05901974Phase 2
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingRecruitingNCT05794880Not applicable
- Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute LeukemiaRecruitingNCT05327894Phase 3
- Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)RecruitingNCT05322850Phase 1/2
- Venetoclax Basket Trial for High Risk Hematologic MalignanciesRecruitingNCT05292664Phase 1
- Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALRecruitingNCT04872478Phase 1
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingNCT04797767Phase 1/2
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyRecruitingNCT04726241Phase 1/2
- Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous LineageRecruitingNCT04440267Phase 2
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingNCT04375631Phase 1
- The OPAL Study: AVM0703 for Treatment of Lymphoid MalignanciesRecruitingNCT04329728Phase 1/2
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationRecruitingNCT04065399Phase 1/2
- Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04047641Phase 1/2
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingNCT03959085Phase 3
- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesRecruitingNCT03802695Phase 1
- Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationRecruitingNCT03683433Phase 2
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic SyndromeRecruitingNCT03670966Phase 1/2
- HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantRecruitingNCT03326921Phase 1
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute LeukemiaRecruitingNCT03128034Phase 1/2
- Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingNCT02115295Phase 2
- Registry of Older Patients With CancerRecruitingNCT01137825
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
- Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesActive, not recruitingNCT05316701Phase 3Results posted
- Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell MembraneActive, not recruitingNCT05146739Phase 1Results posted
- Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1TerminatedNCT04874194Phase 1/2Results posted
- Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
- Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic SyndromesActive, not recruitingNCT03399773Phase 2Results posted
- Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell TransplantCompletedNCT03267186Phase 2Results posted
- Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced ThrombocytopeniaTerminatedNCT03195010Phase 2Results posted
- Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
- Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaActive, not recruitingNCT02879695Phase 1Results posted
- HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation CyclophosphamideCompletedNCT02793544Phase 2Results posted
- Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02728050Phase 1/2Results posted
- Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic MalignanciesTerminatedNCT02419755Phase 2Results posted
- Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaTerminatedNCT02399917Phase 2Results posted
- Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results posted
- Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHDCompletedNCT02220985Phase 2Results posted
- Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute LeukemiaCompletedNCT02135874Phase 2Results posted
- Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT02044796Phase 1/2Results posted
- Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD PreventionCompletedNCT01951885Phase 3Results posted
- Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in ChildrenCompletedNCT01858740Phase 2Results posted
- Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01804101Not applicableResults posted
- Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic SyndromesCompletedNCT01690520Phase 2Results posted
- Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01028716Phase 2Results posted
- Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood TransplantCompletedNCT00796068Phase 2Results posted
- Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseCompletedNCT00719888Phase 2Results posted
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute LeukemiaWithdrawnNCT07498465Phase 1
- Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With HemoblastosisActive, not recruitingNCT06475820Phase 2/3
- SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDSActive, not recruitingNCT06325748Phase 1
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsActive, not recruitingNCT06034470Phase 1
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD ProphylaxisActive, not recruitingNCT06001385Phase 2
- A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory LeukemiaActive, not recruitingNCT05761171Phase 2
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or LymphomaActive, not recruitingNCT05602194Phase 3
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic MalignanciesActive, not recruitingNCT05589896Phase 1/2
- Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With HemoblastosisActive, not recruitingNCT05515029Phase 3
- Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic SyndromeActive, not recruitingNCT05457556Phase 3
- Cryopreserved MMUD BM With PTCy for Hematologic MalignanciesWithdrawnNCT05170828Phase 1
- Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCTStatus unknownNCT05066958Phase 1/2
- Inqovi Maintenance Therapy in Myeloid NeoplasmsActive, not recruitingNCT04980404Phase 1
- Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT04975919Phase 2
- Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)CompletedNCT04942730Phase 2
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation CyclophosphamideActive, not recruitingNCT04904588Phase 2
- Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaActive, not recruitingNCT04898894Phase 1
- Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute LeukemiaActive, not recruitingNCT04872790Phase 1
- Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPALCompletedNCT04827745Phase 2
- Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
- Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant SettingActive, not recruitingNCT04128501Phase 2
- First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT04067336Phase 1/2
- Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute LeukemiaCompletedNCT03957915Early Phase 1
- Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell TransplantationActive, not recruitingNCT03843528Phase 1
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWithdrawnNCT03807063Phase 1